In 2025, Farmak, a leading pharmaceutical manufacturer in Ukraine*, brought 13 new products to market, expanding its portfolio of prescription medicines and dietary supplements.
The new launches include medicines for the treatment of stroke and traumatic brain injury, schizophrenia therapy, sedation, gastroenterological conditions, and women’s health, as well as dietary supplements designed to adjust specialized diets and support reproductive health and hormonal balance. The products are available in a variety of dosage forms, including sachets, tablets, injectable solutions, and infusion solutions.
Today, Farmak’s product portfolio comprises more than 450 medicinal products. The company exports its products to over 60 countries worldwide. In 2025, Farmak further expanded its export geography by entering the markets of China, Sudan, Oman, Kuwait, and Qatar.
Farmak remains one of the largest taxpayers in the pharmaceutical sector. In 2025, the company paid UAH 1.6 billion in taxes and fees to budgets at all levels. Over the past five years, Farmak’s total tax contributions have amounted to UAH 5.6 billion.
Looking ahead, Farmak continues to focus on what matters most—developing high-quality medicines that improve people’s lives every day.
*By sales value of medicinal products, according to Proxima Research data for the first 11 months of 2025.
